Business
IXICO to Present at Innovation Forum
IXICO to Present at Innovation Forum.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 4717C IXICO plc 10 February 2020 \n\n 10 February 2020\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nIXICO to Present at the Annual Shares Magazine/Cenkos Growth and Innovation Forum \non 11th February 2020\n \nIXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that the Company will be attending and presenting at the Shares Magazine/Cenkos Growth and Innovation Forum on Tuesday, 11 February 2020 at the London Business Design Centre.\n \nGiulio Cerroni, IXICO's Chief Executive Officer, will be attending the event and presenting at 12:15pm GMT in the Flowers Room.\n \nShares Magazine/Cenkos Growth and Innovation Forum: \nPresentation: 12:15 PM GMT, 11 February 2020, Flowers Room\nExhibition: 09:00 AM - 5:00 PM GMT, 11 February 2020, Booth 25\nLondon - Business Design Centre, London N1 52 Upper Street, Islington\n \nThe Shares Magazine/Cenkos Growth and Innovation Forum is one of the UK's major growth and technology focussed investment shows connecting investment experts, fund managers, company executives from fast-growing and technology-led London-listed companies. \n \nFor further information please contact: \n \n\n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7498\n\n\n\n\nAlison Howie, Chief Product Officer\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nOptimum Strategic Communications\n\n\n +44 (0) 203 950 9144\n\n\n\n\nMary Clark / Supriya Mathur / Manel Mateus\n\n\n \n\n\n\n\[email protected]\n\n\n \n\n\n\n\n \n \nAbout IXICO\nIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.\n \nOur goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to di...